Rocket Pharmaceuticals, Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Rocket Pharmaceuticals, Inc. has filed its 2023 10-K report detailing financial instruments and corporate history.</b>

AI Summary

ROCKET PHARMACEUTICALS, INC. (RCKTW) filed a Annual Report (10-K) with the SEC on February 27, 2024. Rocket Pharmaceuticals, Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2023. The filing includes information on various financial instruments, including derivative financial instruments, warrants, and stock options. Specific dates related to stock grants and agreements are mentioned, such as the Danon Disease License Agreement with UCSD starting January 1, 2020. The company's business address is located at 350 Fifth Avenue, Suite 7530, New York, NY 10118. Rocket Pharmaceuticals, Inc. was formerly known as Inotek Pharmaceuticals Corp, with a name change date of February 26, 2004.

Why It Matters

For investors and stakeholders tracking ROCKET PHARMACEUTICALS, INC., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Rocket Pharmaceuticals' financial position and operational details for the fiscal year 2023, crucial for investors to assess the company's performance and future prospects. The detailed information on financial instruments, stock options, and historical corporate changes offers insights into the company's capital structure, potential liabilities, and strategic evolution.

Risk Assessment

Risk Level: medium — ROCKET PHARMACEUTICALS, INC. shows moderate risk based on this filing. The company operates in the pharmaceutical industry, which is subject to significant regulatory hurdles, clinical trial risks, and market competition, as indicated by the numerous specific financial instruments and agreements detailed in the filing.

Analyst Insight

Investors should review the detailed financial statements and risk factors in the 10-K to understand the company's financial health and the specific risks associated with its drug development pipeline.

Key Numbers

• 2023-12-31 — Fiscal Year End (Reported fiscal year end)
• 2024-02-27 — Filing Date (Date the 10-K was filed)
• 2004-02-26 — Former Company Name Change Date (Date of name change from Inotek Pharmaceuticals Corp)
• 2834 — SIC Code (Standard Industrial Classification for Pharmaceutical Preparations)

Key Players & Entities

• ROCKET PHARMACEUTICALS, INC. (company) — Filer name
• RCKTW (company) — Ticker symbol
• 2024-02-27T00:00:00.000Z (date) — Filing date
• 20231231 (date) — Fiscal year end
• 0000950170-24-021096 (filing_id) — Accession number
• 350 FIFTH AVENUE SUITE 7530 NEW YORK NY 10118 (address) — Business address
• INOTEK PHARMACEUTICALS CORP (company) — Former company name
• 20040226 (date) — Date of former company name change

FAQ

Risk Factors

• Regulatory Risks [high — regulatory]: The pharmaceutical industry is subject to extensive regulation by government agencies, which can impact product development, approval, and marketing.
• Market Competition [high — market]: The company faces intense competition from other pharmaceutical and biotechnology companies, which can affect market share and pricing.
• Financing Risks [high — financial]: As a development-stage company, Rocket Pharmaceuticals may require significant additional funding, and there is no assurance it will be able to secure such funding on favorable terms.
• Clinical Trial Risks [high — operational]: The success of drug development is uncertain, and clinical trials may fail to demonstrate efficacy or safety, leading to significant delays or discontinuation of programs.

Key Financial Figures

• $0.01 — nge on which registered Common Stock, $0.01 par value RCKT NASDAQ Global Market

Filing Documents

• rckt-20231231.htm (10-K) — 3057KB
• rckt-ex10_13.htm (EX-10.13) — 119KB
• rckt-ex10_23.htm (EX-10.23) — 19KB
• rckt-ex21_1.htm (EX-21.1) — 14KB
• rckt-ex23_1.htm (EX-23.1) — 4KB
• rckt-ex31_1.htm (EX-31.1) — 13KB
• rckt-ex31_2.htm (EX-31.2) — 13KB
• rckt-ex32_1.htm (EX-32.1) — 12KB
• rckt-ex97.htm (EX-97) — 49KB
• img172964561_0.jpg (GRAPHIC) — 112KB
• img172964561_1.jpg (GRAPHIC) — 46KB
• img172964561_2.jpg (GRAPHIC) — 157KB
• 0000950170-24-021096.txt (&nbsp;) — 13942KB
• rckt-20231231.xsd (EX-101.SCH) — 1903KB
• rckt-20231231_htm.xml (XML) — 2384KB

Business

Business 7 Item 1A.

Risk Factors

Risk Factors 36 Item 1B. Unresolved SEC Comments 65 Item 1C. Cybersecurity 65 Item 2.

Properties

Properties 66 Item 3.

Legal Proceedings

Legal Proceedings 67 Item 4. Mine Safety Disclosures 67 PART II. Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 68 Item 6. Reserved 69 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 69 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 79 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 79 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 79 Item 9A.

Controls and Procedures

Controls and Procedures 79 Item 9B. Other Information 80 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 80 PART III Item 10. Directors, Executive Officers, and Corporate Governance 81 Item 11.

Executive Compensation

Executive Compensation 81 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 81 Item 13. Certain Relationships and Related Transactions, and Director Independence 81 Item 14. Principal Accountant Fees and Services 81 PART IV Item 15. Exhibits and Financial Statement Schedules 82 Item 16. Form 10-K Summary 84

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K ("Annual Report") contains forward-looking statements that involve risks and uncertainties, as well as assumptions that, if they do not materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this Annual Report are forward-looking statements. In some cases, you can identify forward-looking statements by words such as "aim," "anticipate," "believe," "can," "contemplate," "continue," "could," "design," "develop," "estimate," "expect," "expand," "future," "hope," "intend," "likely," "may," "plan," "potential," "predict," "project," "pursue," "seek," "should," "strategy," "target," "will," "would," or the negative of these words or other comparable terminology. These forward-looking statements include, but are not limited to, statements about: our ability to meet our anticipated milestones for our various drug candidates with respect to the initiation and timing of clinical studies; federal, state, and non-U.S. regulatory requirements, including regulation of our current or any other future product candidates by the U.S. Food and Drug Administration ("FDA"); the timing of and our ability to submit regulatory filings, including filings with the FDA, and to obtain and maintain FDA or other regulatory authority approval of, or other action with respect to, our product candidates; our competitors' activities, including decisions as to the timing of competing product launches, pricing and discounting; whether safety and efficacy results of our clinical trials and other required tests for approval of our product candidates provide data to warrant progression of clinical trials, poten

B usiness

Item 1. B usiness Overview We are a fully integrated, late-stage biotechnology company focused on the development of first, only and best in class gene therapies, with direct on-target mechanism of action and clear clinical endpoints, for rare and devastating diseases. We have three clinical-stage ex vivo lentiviral vector ("LV") programs, which include programs for: Fanconi Anemia ("FA"), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; Leukocyte Adhesion Deficiency-I ("LAD-I"), a genetic disorder that causes the immune system to malfunction; and Pyruvate Kinase Deficiency ("PKD"), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. In September 2023, the FDA accepted the Biologics License Application ("BLA") and granted priority review for RP-L201 for the treatment of severe LAD-I. Treatments in the FA Phase 2 studies were completed in 2023 with regulatory filings in the United States ("U.S.") and Europe ("EU") for FA anticipated in 2024. Additional work on a gene therapy program for the less common FA subtypes C and G is ongoing. In the U.S., we also have two clinical stage and one pre-clinical stage in vivo adeno-associated virus ("AAV") programs, which include programs for: Danon disease ("DD"), a multi-organ lysosomal-associated disorder leading to early death due to heart failure. The DD program is currently in an ongoing Phase 2 trial. Plakophilin-2 Arrhythmogenic Cardiomyopathy ("PKP2-ACM"), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death. This program received FDA clearance of an Investigational New Drug ("IND") application and we have initiated a Phase 1 study. BAG3 Dilated Cardiomyopathy ("DCM"), which is the most commo

View Full Filing

View this 10-K filing on SEC EDGAR